# Aliskiren Study of Safety and Efficacy in Senior Hypertensives

> **NCT01922141** · PHASE4 · WITHDRAWN · sponsor: **Novartis Pharmaceuticals**

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** Aliskiren
- **DRUG:** Amlodipine
- **DRUG:** Ramipril
- **DRUG:** Hydrochlorothiazide

## Key facts

- **NCT ID:** NCT01922141
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2015-05
- **Primary completion:** 2018-06
- **Final completion:** 2018-06
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2015-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01922141

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01922141, "Aliskiren Study of Safety and Efficacy in Senior Hypertensives". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01922141. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*